StockData
Oruka Therapeutics, Inc. logo

Oruka Therapeutics, Inc. (ORKA) stock

ORKANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$96.32−2.92 (-2.94%)

Close on Nov 17, 2026Market cap $6.38BP/E –Yield –

Oruka Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Oruka Therapeutics's enterprise value was $5.67B on Nov 11, 2026, against $1.11B a year earlier. Over the last 5 years it ranged from $4.37M to $5.67B, with a median of $340.45M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$5.67B+407.6%
2025Dec 31, 2025$1.12B+317.3%
2024Dec 31, 2024$267.75M+4.8%
2023Dec 29, 2023$255.49M-30.2%
2022Dec 30, 2022$365.90M+16.7%
2021Dec 31, 2021$313.48M-20.8%
2020Dec 31, 2020$395.75M+297.3%
2019Dec 31, 2019$99.60M+111.5%
2018Dec 31, 2018$47.08M-73.0%
2017Dec 29, 2017$174.40M-39.2%
2016Dec 30, 2016$287.08M-38.1%
2015Dec 31, 2015$463.50M+107.1%
2014Dec 31, 2014$223.75M-9.6%
2013Dec 31, 2013$247.39M+372.4%
2012Dec 31, 2012$52.37M-56.5%
2011Dec 30, 2011$120.44M–

More Oruka Therapeutics figures

See a number that looks wrong?